News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
19,217 Results
Type
Article (3469)
Company Profile (3)
Press Release (15745)
Multimedia
Podcasts (26)
Webinars (3)
Section
Business (8095)
Career Advice (98)
Deals (1077)
Drug Delivery (26)
Drug Development (2793)
Employer Resources (13)
FDA (628)
Job Trends (657)
News (11439)
Policy (1056)
Tag
40 Under 40 (1)
Academia (71)
Accelerated approval (4)
Adcomms (2)
Allergies (16)
Alliances (1498)
ALS (7)
Alzheimer's disease (42)
Antibody-drug conjugate (ADC) (17)
Approvals (634)
Artificial intelligence (31)
ASCO (21)
Autoimmune disease (29)
Automation (3)
Bankruptcy (9)
Best Places to Work (364)
Biologics (1)
BIOSECURE Act (2)
Biosimilars (27)
BioSpace Insights (6)
Biotechnology (2)
Bladder cancer (4)
Brain cancer (2)
Breast cancer (45)
Cancer (183)
Cardiovascular disease (45)
Career advice (81)
Career pathing (4)
CAR-T (27)
CDC (2)
CDMO (21)
Cell therapy (51)
Cervical cancer (1)
Clinical research (2287)
Collaboration (63)
Commercialization (3)
Company closure (1)
Compensation (6)
Complete response letters (6)
COVID-19 (104)
CRISPR (3)
CRO (1)
C-suite (140)
Data (160)
Depression (3)
Dermatology (3)
Diabetes (9)
Diagnostics (58)
Diversity (1)
Diversity, equity & inclusion (3)
Drug discovery (24)
Drug pricing (39)
Duchenne muscular dystrophy (11)
Earnings (1673)
Editorial (9)
Employer branding (7)
Employer resources (13)
ESMO (7)
Events (1335)
Executive appointments (114)
FDA (714)
Friedreich's ataxia (3)
Frontotemporal dementia (1)
Funding (93)
Gene editing (8)
Generative AI (4)
Gene therapy (50)
GLP-1 (54)
Government (213)
Guidances (17)
Healthcare (382)
Hematology (8)
HIV (1)
Huntington's disease (7)
IgA nephropathy (24)
Immunology and inflammation (33)
Immuno-oncology (7)
Indications (3)
Infectious disease (108)
Inflammatory bowel disease (1)
Inflation Reduction Act (2)
Intellectual property (1)
Interviews (17)
IPO (295)
IRA (14)
Job creations (282)
Job search strategy (76)
JPM (14)
Kidney disease (10)
Labor market (20)
Layoffs (86)
Leadership (3)
Legal (349)
Licensing (7)
Liver cancer (3)
Longevity (2)
Lung cancer (14)
Lung diease (1)
Lymphoma (4)
Machine learning (1)
Management (2)
Manufacturing (73)
Marketing (2)
MASH (5)
Medical device (62)
Medtech (63)
Melanoma (22)
Mergers & acquisitions (794)
Metabolic disorders (46)
mRNA (21)
Multiple sclerosis (18)
Netherlands (1)
Neurodegenerative disease (26)
Neuropsychiatric disorders (7)
Neuroscience (115)
NextGen: Class of 2026 (245)
Non-profit (66)
Now hiring (10)
Obesity (30)
Opinion (47)
Pain (3)
Pancreatic cancer (1)
Parkinson's disease (6)
Partnered (1)
Patents (16)
Patient recruitment (7)
Peanut (10)
People (3806)
Peptides (3)
Pharmacy benefit managers (1)
Phase 1 (645)
Phase 2 (910)
Phase 3 (1029)
Pipeline (275)
Policy (38)
Postmarket research (148)
Preclinical (198)
Prostate cancer (22)
Psychedelics (4)
Radiopharmaceuticals (63)
Rare diseases (55)
Real estate (177)
Recruiting (6)
Regulatory (703)
Reports (3)
Research institute (69)
Resumes & cover letters (24)
Rett syndrome (1)
RNA editing (1)
Schizophrenia (6)
Series A (21)
Series B (23)
Series C (1)
Sickle cell disease (3)
Special edition (8)
Spinal muscular atrophy (46)
Sponsored (4)
Startups (291)
Stomach cancer (2)
Supply chain (11)
Tariffs (25)
The Weekly (26)
Vaccines (25)
Venture capital (36)
Weight loss (19)
Women's health (3)
Date
Last 7 days (24)
Last 30 days (90)
Last 365 days (692)
2026 (643)
2025 (679)
2024 (839)
2023 (819)
2022 (2041)
2021 (1817)
2020 (1403)
2019 (1200)
2018 (965)
2017 (1221)
2016 (911)
2015 (985)
2014 (735)
2013 (602)
2012 (636)
2011 (611)
2010 (623)
Location
Africa (51)
Alabama (2)
Arizona (1)
Asia (1343)
Australia (199)
California (205)
Canada (74)
China (35)
Colorado (7)
Connecticut (13)
Delaware (16)
Europe (4736)
Florida (12)
Georgia (5)
Illinois (14)
India (1)
Indiana (14)
Japan (4)
Kansas (4)
Maryland (14)
Massachusetts (323)
Michigan (6)
Minnesota (6)
Missouri (1)
Nebraska (1)
Nevada (3)
New Hampshire (7)
New Jersey (96)
New Mexico (1)
New York (45)
North Carolina (40)
Northern California (110)
Ohio (8)
Oregon (1)
Pennsylvania (33)
Puerto Rico (1)
Rhode Island (1)
South America (51)
South Carolina (1)
Southern California (64)
Tennessee (2)
Texas (24)
United States (831)
Utah (5)
Virginia (7)
Washington D.C. (3)
Washington State (16)
Wisconsin (3)
19,217 Results for "novartis".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Earnings
Novartis projects slowed growth, pins hopes on billions in pipeline potential
With Kisqali going off patent and decreasing prices impacting sales, Novartis has narrowed sales guidance to 5% growth. But management remains steadfast that they have a plan to get back on track.
November 19, 2026
·
3 min read
·
Annalee Armstrong
Deals
Novartis puts $772M BioArctic deal on ice, skates away from brain-delivery alliance
Novartis is discontinuing a neurodegeneration alliance with BioArctic in which the companies aimed to develop a drug candidate that could cross the blood-brain barrier.
November 3, 2026
·
1 min read
·
Gabrielle Masson
Cardiovascular disease
Details from Novartis’ failed cardiovascular trial offer ‘little silver lining’ for rivals
Full data from the Phase 3 HORIZON trial of Novartis’ pelacarsen failed to show any apparent benefit, leading analysts to further reduce the odds of success for Lp(a)-lowering competitors such as Amgen’s olpasiran.
November 9, 2026
·
4 min read
·
Heather McKenzie
Drug Development
Update: FDA investigates Novartis’ Zolgensma following 9 cases of tumors in treated patients
After Novartis confirmed the reports of tumors in patients who have been treated with the spinal muscular atrophy gene therapy, the FDA will determine if any regulatory action is needed for Zolgensma or for the pharma’s similar product Itvisma.
November 9, 2026
·
4 min read
·
Heather McKenzie
Earnings
Novartis faces $1.9B hit from Avidity fail but maintains confidence in $12B buy
Novartis remains “very happy” with its $12 billion acquisition of Avidity Biosciences, despite a Phase 3 disappointment for the antibody-oligonucleotide conjugate del-desiran.
October 27, 2026
·
4 min read
·
Tristan Manalac
Deals
Novartis bets up to $900M for radioligand therapy from China’s BoomRay
Novartis is the current radiopharma leader with two FDA-approved therapies in Pluvicto and Lutathera.
September 23, 2026
·
2 min read
·
Tristan Manalac
Clinical research
Novartis drags peers down with triple asset stumble
Novartis’ shares fell 13% this week after the report of three separate late-stage asset setbacks. The impact went beyond the Swiss drugmaker, dragging peers down across the market.
September 11, 2026
·
1 min read
·
Annalee Armstrong
Manufacturing
3 steps for taking on Novartis in radiopharma: Curium up first
To successfully challenge Novartis on two planned fronts, Curium will need to overcome the unique challenges posed by radiopharmaceutical supply to get products to patients and win market share.
September 29, 2026
·
4 min read
·
Nick Paul Taylor
Autoimmune disease
Novartis ends mid-stage Fabhalta study in lupus, insists no efficacy or safety issues
Novartis will continue to study Fabhalta in other indications, with late-stage studies in two rare diseases—atypical haemolytic uraemic syndrome and generalized myasthenia gravis—expected to read out later this year and next year, respectively.
October 19, 2026
·
2 min read
·
Tristan Manalac
Neuroscience
Novartis drops $125M for Sironax’s tech to cross blood-brain barrier
Novartis stands alongside Big Pharma peers that have similarly invested in technologies to penetrate the blood-brain barrier, including GSK, Roche and Eli Lilly.
September 17, 2026
·
2 min read
·
Tristan Manalac
1 of 1,922
Next